The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
Abstract
OBJECTIVE: To assess the efficacy and tolerability of adjunctive levetiracetam in patients with uncontrolled generalized tonic-clonic (GTC) seizures associated with idiopathic generalized epilepsies (IGE). METHODS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled adults and children (4 to 65 years) with IGE experiencing >or=3 GTC seizures during the 8-week baseline period (4-week retrospective and 4-week prospective), despite receiving stable doses of one or two antiepileptic drugs (AEDs). Patients were randomized to levetiracetam (target dose 3,000 mg/day for adults; 60 mg/kg/day for children) or placebo and a 4-week titration period was followed by a 20-week evaluation period. RESULTS: Of 229 patients screened, 164 were randomized (levetiracetam, n = 80; placebo, n = 84). Levetiracetam produced a greater mean reduction in GTC seizure frequency per week over the treatment period (56.5%) than placebo (28.2%; p = 0.004). The percentage of patients who had >or=50% reduction of GTC seizure frequency per week (responders) during the treatment period was 72.2% for levetiracetam and 45.2% for placebo (p < 0.001; OR 3.28; 95% CI 1.68 to 6.38). During the first 2-week treatment 64.6% of patients on levetiracetam and 45.2% on placebo (p = 0.018) were classified as responders. During the evaluation period the percent of patients free of GTC seizures (34.2% vs 10.7%; p < 0.001) and all seizure types (24.1% vs 8.3%; p = 0.009) was greater for levetiracetam than placebo. Levetiracetam was well tolerated with 1.3% of patients discontinuing therapy due to adverse events vs 4.8% on placebo. CONCLUSION: Adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalized tonic-clonic seizures in patients with idiopathic generalized epilepsies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., & Arroyo, S. (2008) · Neurology · doi:10.1212/01.wnl.0000303813.95800.0d · Cited by 356
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X.-F., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T. J., Laurenza, A., Patten, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001930 · Cited by 329
Treatment of pediatric epilepsy: European expert opinion, 2007
Wheless, J. W., Clarke, D. F., Arzimanoglou, A., & Carpenter, D. (2007) · Epileptic Disorders · doi:10.1684/epd.2007.0144 · Cited by 295
Trinka, E., Marson, A. G., Van Paesschen, W., Kälviäinen, R., Marovac, J., Duncan, B., Buyle, S., Hallström, Y., Hon, P., Muscas, G. C., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300376 · Cited by 121
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Metadata
- Authors
- Berkovic, S. F., Knowlton, R. C., Leroy, R. F., Schiemann, J., & Falter, U.
- Venue
- Neurology
- Published
- 2007-10-30
- Volume
- 69
- Issue
- 18
- Pages
- 1751-1760
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2098988883
- Cited by
- 257
- References
- 1
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. https://app.cochat.ai/papers/10.1212/01.wnl.0000268699.34614.d3
- The paper
- Berkovic, S. F., Knowlton, R. C., Leroy, R. F., Schiemann, J., & Falter, U. (2007). Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. https://doi.org/10.1212/01.wnl.0000268699.34614.d3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.